Zegbeh Jallah
Stock Analyst at Capital One
(2.00)
# 1,605
Out of 4,667 analysts
26
Total ratings
30%
Success rate
0.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $5.23 | +1,812.05% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.38 | +3,065.39% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $9.21 | +377.74% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $5.64 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $25.86 | +12.14% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $1.07 | +4,385.98% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $9.42 | +643.10% | 2 | May 12, 2022 | |
| SYRS Syros Pharmaceuticals | Maintains: Buy | $200 → $230 | $0.28 | +82,992.49% | 1 | Sep 23, 2021 | |
| RZLT Rezolute | Initiates: Buy | $21 | $4.95 | +324.24% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $21.64 | +523.84% | 2 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $132 | $3.18 | +4,050.94% | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $6 | $0.87 | +586.81% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $9.05 | +507.73% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $2.74 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.03 | +676.70% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.37 | +5,334.78% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $5.23
Upside: +1,812.05%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.38
Upside: +3,065.39%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $9.21
Upside: +377.74%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $5.64
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $25.86
Upside: +12.14%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $1.07
Upside: +4,385.98%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $9.42
Upside: +643.10%
Syros Pharmaceuticals
Sep 23, 2021
Maintains: Buy
Price Target: $200 → $230
Current: $0.28
Upside: +82,992.49%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $4.95
Upside: +324.24%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $21.64
Upside: +523.84%
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $3.18
Upside: +4,050.94%
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.87
Upside: +586.81%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $9.05
Upside: +507.73%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $2.74
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $1.03
Upside: +676.70%
Dec 18, 2019
Initiates: Buy
Price Target: $20
Current: $0.37
Upside: +5,334.78%